Wall Street analysts expect that REGENXBIO Inc. (NASDAQ:RGNX) will post ($0.74) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for REGENXBIO’s earnings. REGENXBIO posted earnings per share of ($0.69) during the same quarter last year, which indicates a negative year-over-year growth rate of 7.2%. The company is expected to issue its next earnings results on Wednesday, November 8th.

On average, analysts expect that REGENXBIO will report full-year earnings of ($2.74) per share for the current year, with EPS estimates ranging from ($2.80) to ($2.67). For the next fiscal year, analysts expect that the firm will post earnings of ($3.21) per share, with EPS estimates ranging from ($3.24) to ($3.18). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover REGENXBIO.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.34. The business had revenue of $6.56 million during the quarter. REGENXBIO had a negative return on equity of 38.74% and a negative net margin of 839.87%.

A number of equities research analysts have issued reports on the stock. BidaskClub raised shares of REGENXBIO from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th. Zacks Investment Research raised shares of REGENXBIO from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a research note on Saturday, August 12th. Evercore ISI assumed coverage on shares of REGENXBIO in a research note on Wednesday, August 16th. They set an “outperform” rating and a $25.00 target price for the company. Finally, Chardan Capital reissued a “buy” rating and set a $75.00 target price (up previously from $55.00) on shares of REGENXBIO in a research note on Tuesday, September 5th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $37.00.

TRADEMARK VIOLATION NOTICE: This story was first posted by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/09/12/zacks-brokerages-expect-regenxbio-inc-rgnx-will-announce-earnings-of-0-74-per-share.html.

Shares of REGENXBIO (NASDAQ RGNX) opened at 25.65 on Tuesday. REGENXBIO has a 12-month low of $12.82 and a 12-month high of $26.35. The firm’s market capitalization is $792.43 million. The stock’s 50 day moving average price is $20.66 and its 200-day moving average price is $19.84.

In related news, insider Stephen Yoo sold 32,658 shares of REGENXBIO stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $25.00, for a total value of $816,450.00. Following the transaction, the insider now owns 31,803 shares in the company, valued at approximately $795,075. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Donald J. Hayden, Jr. sold 20,000 shares of REGENXBIO stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $24.95, for a total transaction of $499,000.00. Following the completion of the transaction, the director now owns 20,000 shares in the company, valued at approximately $499,000. The disclosure for this sale can be found here. In the last ninety days, insiders sold 91,898 shares of company stock valued at $2,141,135. 17.00% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Redmile Group LLC raised its holdings in REGENXBIO by 35.4% in the 2nd quarter. Redmile Group LLC now owns 1,718,671 shares of the biotechnology company’s stock worth $33,944,000 after acquiring an additional 449,540 shares during the period. Perceptive Advisors LLC raised its holdings in REGENXBIO by 8.9% in the 1st quarter. Perceptive Advisors LLC now owns 1,396,244 shares of the biotechnology company’s stock worth $26,947,000 after acquiring an additional 113,958 shares during the period. JPMorgan Chase & Co. raised its holdings in REGENXBIO by 4.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,226,835 shares of the biotechnology company’s stock worth $24,230,000 after acquiring an additional 51,041 shares during the period. Vanguard Group Inc. raised its holdings in REGENXBIO by 10.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,082,461 shares of the biotechnology company’s stock worth $21,379,000 after acquiring an additional 100,944 shares during the period. Finally, Citadel Advisors LLC raised its holdings in REGENXBIO by 65.4% in the 2nd quarter. Citadel Advisors LLC now owns 926,176 shares of the biotechnology company’s stock worth $18,292,000 after acquiring an additional 366,289 shares during the period. Hedge funds and other institutional investors own 73.23% of the company’s stock.

About REGENXBIO

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Get a free copy of the Zacks research report on REGENXBIO (RGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.